Ocular Therapeutix (OCUL) Profit After Tax (2013 - 2026)

Ocular Therapeutix has reported Profit After Tax for 14 years, with the latest figure at -$78.8 million in Q2 2026.

• Profit After Tax for Q2 2026 came in at -$78.8 million, down 16.15% year-over-year; the trailing twelve-month figure through Jun 2026 was -$301.4 million (down 39.08% YoY), and the FY2025 annual result was -$265.9 million, down 37.43% from the prior year.
• Profit After Tax grew to -$78.8 million in Q2 2026, from -$88.6 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$516000.0 in Q3 2023 and troughed at -$88.6 million in Q1 2026.
• A 5-year average of -$43.3 million and a median of -$40.1 million in 2024 frame the typical range for Profit After Tax.
• The widest annual swing landed in 2023, when Profit After Tax surged 97.87%; it then tumbled 6972.29% in 2024.
• A 5-year view of Profit After Tax shows it stood at -$15.5 million in 2022, then tumbled by 88.01% to -$29.2 million in 2023, then sank by 65.6% to -$48.4 million in 2024, then plunged by 33.62% to -$64.7 million in 2025, then declined by 21.82% to -$78.8 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$78.8 million in Q2 2026, -$88.6 million in Q1 2026, and -$64.7 million in Q4 2025.